Table 2.
Prognostic significance of PD-1/PD-L2 expression in gastric and esophageal cancer.
| Author | Number of Patients | Type of Cancer | Histology | Disease Stage | Percentage of Positivity | Prognosis | Prognostic Value | Reference | |
|---|---|---|---|---|---|---|---|---|---|
| PD-1 | Chen K et al. | 349 | esophageal cancer | SCC | localized | 33.5% | no impact | no impact | [51] |
| Wu Y et al. | 340 | gastric cancer | adenocarcinoma | all stages | 22.6% | better | improved OS | [52] | |
| Böger C et al. | 465 | gastric cancer | adenocarcinoma | all stages | primary cancer 53.8%, liver metastases 73.3% | better | improved tumor specific survival | [12] | |
| Eto S et al. | 105 | gastric cancer | adenocarcinoma | II/III | 26.7% | worse | worse DFS | [16] | |
| Kollmann D et al. | 168 | esophageal cancer | adenocarcinoma | localized | tumor cells 77.4%, immune cells 81% | worse | worse OS and DFS | [30] | |
| PD-L2 | Seo AN et al. | 116 | gastric cancer | adenocarcinoma | localized | tumor cells 21.6%, stromal cells 38.8% | no impact | not statistically significant trend towards-improved DFS | [27] |
| Hsieh CC et al. | 150 | esophageal cancer | SCC | localized | 42% | no impact | no impact | [29] | |
| Tanaka K et al. | 180 | esophageal cancer | SCC | localized | 48.3% | worse | worse OS for patients after neoadjuvant chemotherapy | [31] |
SCC: squamous cell cancer, OS: overall survival, DFS: disease free survival.